SO01
CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL CHEMOTHERAPY FOR PERIOTONEAL CARCINOMATOSIS – 208 CONSECUTIVE PATIENTS

Abstract

Purpose:   Peritoneal carcinomtosis (PC) is uniformly regard ed as a terminal disease with a median survival of 1–6 months and few treatment options. As improved understanding of tumour biology evolved, PC is increasingly recognized as locoregional disease. The aim of this study to report our experience with our 208 consecutive patients with peritoneal carcinomatosis treated by cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC).Methodology:   From January 1997 to September 2008, the clinical and treatment‐related data of 208 patients with PC were entered into a prospective database. The CRS was performed using peritonectomy procedures and the IPC was performed using Mitomycin C for gastrointestinal tumours with Cisplatin and Doxorubicin added for peritoneal mesothelioma at 42 deg Celsius via the Coliseum technique.Results:   The median follow‐up period was 36 months (Range: 1–89 months). The hospital mortality was 3%. The overall morbidity rate was 43% with grade 1 and 2 mortality in 75 patients, grade 3 complications in 49 patients and grade 4 complications in 24 patients. The overall median survival was 82 months with 1‐, 3‐ and 5‐ year actuarial survival of 85%, 70% and 70% respectively. The median survival rates for pseudomxyma peritonei (n = 102), colorectal carcinoma (n = 53) and peritoneal mesothelioma (n = 25) were 82, 30 and 30 months respectively.Conclusion:   CRS and IPC for PC can be performed with acceptable mortality and morbidity as for other major gastrointestinal surgeries with satisfactory long term survival results.